The executive who brought Novo Nordisk’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it https://t.co/993aEbipku ...

Company Outlook - Stada Arzneimittel AG 更有利于今年秋季进行首次公开募股 (IPO)[1] - 德国制药商 Stada Arzneimittel AG 的 CEO 提高了欧洲市场的预期，此前该公司推迟了今年的计划[1]

Novo shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a serious form of liver disease https://t.co/Fi1V1nX2Rn ...

Leadership Change - Bristol-Myers CEO is stepping down after six years [1] - The move is considered a surprise as the company seeks its next successful drug [1] Industry Focus - The pharmaceutical company is in a race to discover its next blockbuster drug [1]

Market Assessment - HC Wainwright analysts suggest Sarepta shares have zero value [1] - This assessment follows regulatory interactions that could lead to market withdrawal of Elevidys treatment [1] Regulatory Impact - US regulators' actions could result in the withdrawal of Sarepta's Elevidys treatment from the market [1]